ESSA Pharma Files Definitive Proxy Statement

TL;DR

ESSA Pharma filed its proxy statement, get ready for shareholder votes.

AI Summary

ESSA Pharma Inc. filed a Definitive Proxy Statement (DEFA14A) on September 10, 2025. This filing is related to the company's proxy materials, which are typically used for shareholder meetings to vote on corporate matters. The filing does not appear to contain specific financial transactions or proposals beyond the standard proxy statement information.

Why It Matters

This filing indicates ESSA Pharma is proceeding with standard corporate governance procedures, likely preparing for a shareholder meeting where important company decisions will be voted upon.

Risk Assessment

Risk Level: low — This is a routine regulatory filing for a public company and does not inherently indicate new risks or significant changes.

Key Players & Entities

• ESSA Pharma Inc. (company) — Registrant
• 0001104659-25-088772 (filing_id) — Accession Number
• 20250910 (date) — Filing Date

FAQ

Filing Documents

• tm2525632d2_defa14a.htm (DEFA14A) — 56KB
• 0001104659-25-088772.txt ( ) — 57KB

01 Other Events

Item 8.01 Other Events. On September 10, 2025, ESSA Pharma Inc. (the " Company ") issued a press release announcing its intention to adjourn the special meeting of the holders of common shares of the Company (" Common Shares "), optionholders and warrantholders (the " Special Meeting ") scheduled to occur on September 10, 2025 to consider and approve the Company's previously announced transaction with XenoTherapeutics, Inc. (" Xeno "), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares. The Special Meeting will be adjourned to 2:00 p.m. (Pacific Time) on September 29, 2025. The Special Meeting will still be held online via a live interactive webcast on the internet at https://meetnow.global/MHPMJ4R. Shareholders of record who have already voted do not need to take any action at this time. A copy of the press release is attached hereto as Exhibit 99.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward Looking Statements

Forward Looking Statements This communication, and any related oral statements, contains certain information which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, " forward-looking statements "). Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction, and other statements that are not statements of historical facts. In this communication, these forward-looking statements are based on the Company 's current expectations, estimates and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management's beliefs and certain assumptions made by the Company, all of which are beyond the ability of the Company to control or predict, and which may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof. Such statements reflect the Company's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the date of such sta

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ESSA PHARMA INC. (Registrant) Date: September 10, 2025 By: /s/ David Wood Name: David Wood Title: Chief Financial Officer Exhibit 99.1 Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025 Adjournment to provide time for continued discussions regarding possible revised financial terms of transaction with XenoTherapeutics SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, Sept. 10, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that the Board of Directors of the Company has approved an adjournment of the special meeting of the holders of common shares of the Company (“Common Shares” and the holders of such Common Shares, the “Shareholders”), optionholders and warrantholders (the “Special Meeting”) scheduled to occur on September 10, 2025 to consider and approve the Company’s previously announced transaction with XenoTherapeutics, Inc. (“Xeno”), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the “Transaction” or the “Arrangement”). ESSA is adjourning the Special Meeting to continue discussions concerning the terms of the Transaction, including the Company’s estimated cash forecast and upfront cash available for distribution to its shareholders in the Transaction. The Special Meeting will be adjourned to 2:00 p.m. (Pacific Time) on September 29, 2025. The Special Meeting will still be held online via a live interactive webcast on the internet at https://meetnow.global/MHPMJ4R. Shareholders of record who have already voted do not need to take any action at this time. The hearing of ESSA’s application to the British Columbia Supreme

View Full Filing

View this DEFA14A filing on SEC EDGAR